Targeted agents in triple negative breast cancer (Homo sapiens)
From WikiPathways
Description
Schematic of the most relevant molecular pathways and targeted agents in TNBC. Tyrosine kinase receptor is activated upon binding of growth factors leading to activation of signaling pathways. PI3K/AKT pathway and inhibitor drugs: Phosphorylated PI3K activate AKT. The activation of AKT triggers downstream protein complexes mTORC activation that initiate gene transcription and promote cell growth. AR pathway is activated in LAR subtype tumors. Platinum drugs act through DNA damaging mechanism. PARP inhibitors induce “synthetic lethality” in BRCA deficient tumors.
Quality Tags
Ontology Terms
Saving...Bibliography
- Vagia E, Mahalingam D, Cristofanilli M; ''The Landscape of Targeted Therapies in TNBC.''; Cancers (Basel), 2020 PubMed Europe PMC Scholia
History
View all... |
External references
DataNodes
| View all... |
| Name | Type | Database reference | Comment |
|---|---|---|---|
| 4EBP1 | GeneProduct | ||
| AKT1 | GeneProduct | 207 (Entrez Gene)  | |
| INPP48 | GeneProduct | ||
| IRS1 | GeneProduct | 3667 (Entrez Gene) | |
| MK2206 | Metabolite | ||
| MTOR | GeneProduct | 2475 (Entrez Gene) | |
| PDK1 | GeneProduct | 5163 (Entrez Gene) | |
| PI3k | GeneProduct | ||
| PIP2 | GeneProduct | ||
| PIP3 | GeneProduct | ||
| PTEN | GeneProduct | 5728 (Entrez Gene) | |
| S6K | GeneProduct | ||
| TCS1/2 | GeneProduct | ||
| alpelisib | Metabolite | Q27074391 (Wikidata) | |
| buparlisib | Metabolite | Q25100534 (Wikidata) | |
| dactolisib | Metabolite | Q4835503 (Wikidata) | |
| everolimus | Metabolite | Q421052 (Wikidata) | |
| mTORC1 | GeneProduct | ||
| mTORC2 | GeneProduct | ||
| pictilisib | Metabolite | Q27088388 (Wikidata) | |
| temsirolimus | Metabolite | Q7699074 (Wikidata) |
Annotated Interactions
No annotated interactions
